PA21
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hemodialysis
Conditions
Hemodialysis, Hyperphosphatemia
Trial Timeline
Apr 29, 2013 → Dec 3, 2013
NCT ID
NCT01850641About PA21
PA21 is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01850641. Target conditions include Hemodialysis, Hyperphosphatemia.
What happened to similar drugs?
2 of 15 similar drugs in Hemodialysis were approved
Approved (2) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01852682 | Phase 3 | Completed |
| NCT01850641 | Phase 3 | Completed |
| NCT01833494 | Phase 3 | Completed |
Competing Products
20 competing products in Hemodialysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| ASP7991 | Astellas Pharma | Phase 1 | 29 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| ASP1585 | Astellas Pharma | Phase 2 | 35 |
| Kiklin capsules | Astellas Pharma | Pre-clinical | 26 |
| Doravirine | Merck | Approved | 43 |
| BPS804 + Placebo | Novartis | Phase 2 | 27 |
| PA21 + Sevelamer hydrochloride | Kissei Pharmaceutical | Phase 3 | 40 |
| PA21 + PA21 + PA21 + PA21 + Placebo | Kissei Pharmaceutical | Phase 2 | 35 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 40 |
| [¹⁴C]Etelcalcetide | Amgen | Phase 1 | 29 |
| Epoetin Hospira | Pfizer | Phase 3 | 40 |
| Epoetin Hospira | Pfizer | Phase 3 | 40 |
| sodium thiosulfate | Sanofi | Pre-clinical | 26 |
| Enoxaparine | Sanofi | Approved | 43 |
| Alirocumab 150 MG/ML [Praluent] | Regeneron Pharmaceuticals | Phase 3 | 36 |